Published in Cancer Weekly, April 26th, 2005
"In patients with recurrent malignant glioma, t-MDS and acute leukemia are rare adverse effects because the median survival after relapse is limited. We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)," scientists in Taiwan reported.
"A cytogenetic study showed del(3)(q11.1). MDS was diagnosed 8.4 months after beginning TMZ," explained Y.W. Su and colleagues, Mackay Memorial Hospital.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.